Lanean...
A potent KRAS macromolecule degrader specifically targeting tumours with mutant KRAS
Tumour-associated KRAS mutations are the most prevalent in the three RAS-family isoforms and involve many different amino-acids. Therefore, molecules able to interfere with mutant KRAS protein are potentially important for wide-ranging tumour therapy. We describe the engineering of two RAS degraders...
Gorde:
| Argitaratua izan da: | Nat Commun |
|---|---|
| Egile Nagusiak: | , , |
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
Nature Publishing Group UK
2020
|
| Gaiak: | |
| Sarrera elektronikoa: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7319959/ https://ncbi.nlm.nih.gov/pubmed/32591521 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41467-020-17022-w |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|